{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"Non progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Progressive disease <= 6 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Progressive disease <= 12 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}],"title":"Progressive disease <= 24 weeks"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Number of participants with liver metastases at baseline who has a documented disease progression as per RECIST1.1.","groups":[{"description":"Participants received 5x10e7 pfu TG4001 subcutaneously along with 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG000","title":"Phase II Part 2 - Cohort B - Participants With Liver Metastases - TG4001 5x10e7 Pfu + Avelumab"},{"description":"Participants received 800 mg avelumab intravenously until disease progression, unacceptable toxicity, participant withdrawal from study for any reason.","id":"OG001","title":"Phase II Part 2 - Cohort B - Participants With Liver Metastases - Avelumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase II part 2 Cohort B: All randomized participants administered with at least one dose of IMP(s) according to allocation at randomization (FAS). One participant (cohort B - Avelumab) was excluded from analysis because no IMP has been administered.\n\nPhase Ib, Phase II part 1 and Phase II part 2 Cohort A, proportion of progressive disease has not been defined as secondary endpoint. Therefore phase Ib, Phase II part 1 and Phase II part 2 Cohort A are not included in the analysis population.","reportingStatus":"POSTED","timeFrame":"From randomization: every 6 weeks up to 24 weeks.","title":"Proportion of Progressive Disease Phase II Part 2 Cohort B","type":"SECONDARY","unitOfMeasure":"Participants"}